[
  {
    "ts": null,
    "headline": "Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finnhub.io/api/news?id=b8308c92a4d731ddec2d1bfcb386b094c6bb120a23c04d98bf95b55fbadaae1b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759499102,
      "headline": "Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term",
      "id": 136968297,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
      "url": "https://finnhub.io/api/news?id=b8308c92a4d731ddec2d1bfcb386b094c6bb120a23c04d98bf95b55fbadaae1b"
    }
  },
  {
    "ts": null,
    "headline": "Is Quest Diagnostics' (DGX) Shield Partnership Transforming Its Role in Preventive Health Innovation?",
    "summary": "Guardant Health and Quest Diagnostics previously announced a multi-year collaboration to offer the FDA-approved Shield blood-based colorectal cancer screening test to Quest's large U.S. provider network, leveraging Quest's connectivity to approximately 650,000 clinician and hospital accounts and nationwide network of patient service centers. This partnership highlights Quest's expanding role in making innovative, non-invasive cancer screening more accessible, as well as its growing...",
    "url": "https://finnhub.io/api/news?id=5d945741db2f1aa47d8013e428c64741021266b03633001cfeb30c938472378d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759494464,
      "headline": "Is Quest Diagnostics' (DGX) Shield Partnership Transforming Its Role in Preventive Health Innovation?",
      "id": 136964518,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Guardant Health and Quest Diagnostics previously announced a multi-year collaboration to offer the FDA-approved Shield blood-based colorectal cancer screening test to Quest's large U.S. provider network, leveraging Quest's connectivity to approximately 650,000 clinician and hospital accounts and nationwide network of patient service centers. This partnership highlights Quest's expanding role in making innovative, non-invasive cancer screening more accessible, as well as its growing...",
      "url": "https://finnhub.io/api/news?id=5d945741db2f1aa47d8013e428c64741021266b03633001cfeb30c938472378d"
    }
  },
  {
    "ts": null,
    "headline": "Barclays Maintains Quest Diagnostics (DGX) Equal-Weight Recommendation",
    "summary": "Barclays Maintains Quest Diagnostics (DGX) Equal-Weight Recommendation",
    "url": "https://finnhub.io/api/news?id=1b24a5b5cd48e440872f24078eac69f6e618a7e449922e118f2c48be0d6c5d60",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759449884,
      "headline": "Barclays Maintains Quest Diagnostics (DGX) Equal-Weight Recommendation",
      "id": 136958498,
      "image": "",
      "related": "DGX",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=1b24a5b5cd48e440872f24078eac69f6e618a7e449922e118f2c48be0d6c5d60"
    }
  }
]